Inhibitors of tyk2
US-2024425484-A1 · Dec 26, 2024 · US
US9108957B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9108957-B2 |
| Application number | US-201013262396-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2010 |
| Priority date | Apr 2, 2009 |
| Publication date | Aug 18, 2015 |
| Grant date | Aug 18, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A compound represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom, C—F or the like; R 1 represents a C 1 -C 3 alkyl group; Y represents oxygen atom or N—R 7 ; R 2 , R 3 , R 4 , R 5 , R 6 and R 7 each independently represents hydrogen atom, a C 1 -C 6 alkyl group, or a group represented by the formula (II): which is used for preventive and/or therapeutic treatment of a disease caused by tau protein kinase 1 hyperactivity such as a neurodegenerative diseases (e.g. Alzheimer disease).
Opening claim text (preview).
The invention claimed is: 1. A compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein Z represents nitrogen atom or C—F; R 1 represents a C 1 -C 3 alkyl group; Y represents an oxygen atom; R 2 , R 3 , R 4 , R 5 , and R 6 may be the same or different and each independently represents hydrogen atom…
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.